The ACTME study is an investigator initiated, single center phase I/II clinical trial for
patients with progressive unresectable stage III or stage IV melanoma. The trial consists of
both a phase I part to determine safety and feasibility and a phase II part to evaluate first
clinical activity of IFN-alpha, nivolumab and TIL. The treatment with IFN-alpha will be added
after the combination of TIL and nivolumab has proven to be safe.